Orlistat / GSH Cancer Research Results

OLST, Orlistat: Click to Expand ⟱
Features:

Orlistat (tetrahydrolipstatin; anti-obesity drug; OTC 60 mg, Rx 120 mg). A potent, minimally absorbed gastrointestinal lipase inhibitor that reduces dietary fat absorption (~30% at 120 mg TID).

Primary mechanisms (conceptual rank):
1) Irreversible inhibition of gastric + pancreatic lipases (↓ triglyceride hydrolysis)
2) ↓ Chylomicron formation → ↓ systemic lipid flux
3) Secondary metabolic shifts (weight loss–mediated insulin sensitivity changes)

Bioavailability / PK relevance: Very low systemic absorption (<1%); primary action is intraluminal in gut. Most systemic mechanistic cancer data derive from higher in-vitro concentrations or off-target effects (e.g., FASN inhibition).

In-vitro vs oral exposure: Many anti-cancer studies use concentrations likely exceeding achievable plasma levels from standard dosing (qualifier: high concentration only for direct tumor cytotoxicity).

Clinical evidence status: Approved for obesity; cancer evidence largely preclinical/observational; no robust oncology RCT indication.

Inhibits lipase and is used to facilitate weight loss.

Orlistat — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Fatty Acid Synthase (FASN) ↓ (high concentration only) ↔ (low FASN dependence) R/G Lipid synthesis blockade; apoptosis Well-known off-target in vitro; many tumors overexpress FASN. Clinical relevance limited by low systemic exposure.
2 Lipid availability / metabolic flux ↓ (indirect) ↓ (systemic) G Reduced lipid supply Weight-loss–mediated effect; may indirectly reduce pro-tumor metabolic signaling (insulin/IGF axis).
3 PI3K/AKT/mTOR ↓ (model-dependent) ↔ / ↓ (metabolic improvement) R/G Reduced anabolic signaling Often secondary to lipid stress or metabolic shifts; not primary gut mechanism.
4 Apoptosis (caspase activation) ↑ (high concentration only) ↔ R/G Programmed cell death Observed in cancer lines at supra-physiologic levels; translation uncertain.
5 ROS / lipid peroxidation stress ↑ (lipid stress–related; model-dependent) ↔ P/R Metabolic oxidative stress Linked to FASN inhibition; not central to approved mechanism.
6 NRF2 axis ↔ (insufficient evidence) ↔ R/G Not a dominant axis No consistent evidence of primary NRF2 modulation at therapeutic exposure.
7 Ferroptosis (lipid metabolism link) ↑ (theoretical / model-dependent) ↔ R/G Lipid vulnerability shift FASN inhibition could alter lipid composition; ferroptosis relevance remains investigational.
8 HIF-1α / Warburg coupling ↓ (indirect; metabolic improvement) ↔ G Reduced pro-growth metabolic signaling Likely secondary to weight loss and insulin reduction rather than direct tumor action.
9 Ca²⁺ signaling ↔ ↔ P/R No primary role Not a recognized mechanistic axis for orlistat.
10 Clinical Translation Constraint ↓ (constraint) ↓ (constraint) — Minimal systemic exposure Low absorption limits direct anti-tumor applicability; GI side effects and fat-soluble vitamin malabsorption noted.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
GSH, Glutathione: Click to Expand ⟱
Source:
Type:
Glutathione (GSH) is a thiol antioxidant that scavenges reactive oxygen species (ROS), resulting in the formation of oxidized glutathione (GSSG). Decreased amounts of GSH and a decreased GSH/GSSG ratio in tissues are biomarkers of oxidative stress.
Glutathione is a powerful antioxidant found in every cell of the body, composed of three amino acids: cysteine, glutamine, and glycine. It plays a crucial role in protecting cells from oxidative stress, detoxifying harmful substances, and supporting the immune system.
cancer cells can have elevated levels of glutathione, which may help them survive in the oxidative environment created by the immune response and chemotherapy. This can make cancer cells more resistant to treatment.
While glutathione can be obtained from certain foods (like fruits, vegetables, and meats), its absorption from supplements is debated. Some people take N-acetylcysteine (NAC) or other precursors to boost glutathione levels, but the effects on cancer prevention or treatment are still being studied.
Depleting glutathione (GSH) to raise reactive oxygen species (ROS) is a strategy that has been explored in cancer research and therapy.
Many cancer cells have altered redox states and may rely on GSH to survive. Increasing ROS levels can induce stress in these cells, potentially leading to cell death.
Certain drugs and compounds can deplete GSH levels. For example, agents like buthionine sulfoximine (BSO) inhibit the synthesis of GSH, leading to its depletion.
Cancer cells tend to exhibit higher levels of intracellular GSH, possibly as an adaptive response to a higher metabolism and thus higher steady-state levels of reactive oxygen species (ROS).

"...intracellular glutathione (GSH) exhibits an astounding antioxidant activity in scavenging reactive oxygen species (ROS)..."
"Cancer cells have a high level of GSH compared to normal cells."
"...cancer cells are affluent with high antioxidant levels, especially with GSH, whose appearance at an elevated concentration of ∼10 mM (10 times less in normal cells) detoxifies the cancer cells." "Therefore, GSH depletion can be assumed to be the key strategy to amplify the oxidative stress in cancer cells, enhancing the destruction of cancer cells by fruitful cancer therapy."

The loss of GSH is broadly known to be directly related to the apoptosis progression.
Scientific Papers found: Click to Expand⟱
1251- RT,  OLST,    Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions
- in-vitro, BC, MCF-7 - in-vitro, PC, PANC1 - in-vivo, NA, NA
TumVol↓, *CEA↓, *FASN↓, *ROS↓, *MDA↓, *GSH↑, Apoptosis↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

Apoptosis↑, 1,  

Functional Outcomes ⓘ

TumVol↓, 1,  
Total Targets: 2

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

GSH↑, 1,   MDA↓, 1,   ROS↓, 1,  

Core Metabolism/Glycolysis ⓘ

FASN↓, 1,  

Migration ⓘ

CEA↓, 1,  

Clinical Biomarkers ⓘ

CEA↓, 1,  
Total Targets: 6

Scientific Paper Hit Count for: GSH, Glutathione
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:14  Target#:137  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page